Deletion in a regulatory region is associated with underexpression of miR-148b‑3p in patients with prostate cancer.

Autor: Bergez-Hernández F; Postgraduate in Biomedical Sciences, Faculty of Chemical-Biological Sciences, Autonomous University of Sinaloa, Culiacán, 80010 Sinaloa, México., Luque-Ortega F; Basic Sciences Laboratory, Faculty of Dentistry, Autonomous University of Sinaloa, Culiacán, 80100 Sinaloa, México., García-Magallanes N; Laboratory of Biomedicine and Molecular Biology, Biotechnology Engineering, Polytechnic University of Sinaloa, Mazatlán, 82199 Sinaloa, México., Alvarez-Arrazola M; Alvarez and Arrazola Radiologists, Mazatlán, 82140 Sinaloa, México., Arámbula-Meraz E; Postgraduate in Biomedical Sciences, Faculty of Chemical-Biological Sciences, Autonomous University of Sinaloa, Culiacán, 80010 Sinaloa, México.; Laboratory of Genetics and Molecular Biology, Faculty of Chemical-Biological Sciences, Autonomous University of Sinaloa, Culiacán, 80010 Sinaloa, México.
Jazyk: angličtina
Zdroj: Biomedical reports [Biomed Rep] 2024 Jan 30; Vol. 20 (3), pp. 52. Date of Electronic Publication: 2024 Jan 30 (Print Publication: 2024).
DOI: 10.3892/br.2024.1740
Abstrakt: Prostate cancer (PCa) is the leading cause of cancer-related death in men. This pathology is complex and heterogeneous; therefore, elucidating the molecular mechanisms that lead to its origin and progression is imperative. MicroRNAs (miRNAs or miRs) are part of the epigenetic machinery that regulates the expression of human genes, therefore, mutations in the genes that encode them can lead to a dysregulation in their expression, which directly impacts their target genes, which could be oncogenes or tumor suppressor genes. In PCa several dysregulated expression levels of miRNAs are associated with perturbed cellular processes. A differential expression of miRNAs such as miR-145-5p and miR-148-3p has been observed in PCa, possibly due to mutations in regions near the miRNAs. However, the molecular mechanisms that lead to the dysregulation of these miRNAs still need to be clarified. Therefore, the present study aimed to analyze the expression of miRNAs and their relationship with mutations in patients with and without PCa. In total, 71 patients were analyzed: 41 of whom had PCa (CAP group) and 30 with benign pathology (BPD group). Underexpression was observed in miR-145-5p and miR-148b-3p in PCa patients (P=0.03 and P=0.001, respectively). In miR-145-5p, no mutations related to its expression were identified. For miR-148b-3p, a set of mutations were identified in the chr12:54337042/54337043 region, which were grouped into the mutation named DelsAAG. Although this mutation's abnormal allele is related to PCa (P=0.017), a statistically significant difference was observed in the expression of miR-148b-3p between carriers and non-carriers of the mutated allele, identifying a mechanism likely to be involved in the miR-148b-3p dysregulation.
Competing Interests: The authors declare that they have no competing interests.
(Copyright: © Bergez-Hernández et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje